Table 1.

Characteristics of the included studies

Studies	Number (C/E)	Age	Sex (F/M)	Regimens	PFS (C/E, months)
Wu F [12]	25/25	37–74	15/35	GNE vs GN	5.72 ± 0.89/6.90 ± 1.15
Song WC [13]	30/30	33–74	26/34	GPE vs GP	–
Wang ZF [14]	30/34	35–70	3/61	GPE vs GP	7.35 ± 0.52/13.41 ± 1.23
Chen Q [15]	19/21	65–85	–	GE vs G	3.7/4
Lv Y [16]	10/10	60–83	4/16	DPE vs DP	–
Yang L [17]	37/35	–	13/59	GPE vs GP	5.5/7.0
Zheng X [18]	40/40	60–69	29/51	GPE vs GP	6.12 ± 1.78/9.51 ± 2.15
Wang W [19]	50/50	51–56	40/60	PPE vs PP	6.3/8.4
Xun Yu [20]	14/12	46.78–65.88	–	GCE vs GC	5.1 ± 0.6/8.2 ± 1.3
Shi HL [21]	6/3	37–74	–	NPE vs NP	–
Yang L [22]	10/24	33–78	–	VPE vs VP	–
Wang QZ [23]	29/29	–	12/46	DPE vs DP	4.97/7.17
Zhang YY [24]	26/27	53–54	6/53	GPE vs GP	6.5/8.3
Hong S [25]	52/98	32–80	14/136	GPE vs GP	–

Note: The dashes represent no data;

C the control group, E the experimental group, F female, M male; GNE gemcitabine + nedaplatin + Endostar, GN gemcitabine + nedaplatin, GPE gemcitabine + cisplatin + Endostar, GP gemcitabine + cisplatin, GE gemcitabine + Endostar, G gemcitabine, DPE docetaxel + cisplatin + Endostar, DP docetaxel + cisplatin, PPE paclitaxel + cisplatin + Endostar, PP paclitaxel + cisplatin, GCE gemcitabine + carboplatin + Endostar, GC gemcitabine + carboplatin, NPE norvincristine + cisplatin + Endostar, NP norvincristine + cisplatin, VPE vinorelbine + cisplatin + Endostar, VP vinorelbine + cisplatin